Seasonal influenza continues to place a significant strain on pediatric health across Europe, often resulting in a surge of primary care visits and widespread school absenteeism. Though, new evidence suggests that pediatric flu vaccines provide robust, real-world protection for children, though the level of efficacy varies significantly depending on the specific strain of the virus circulating each year.
A comprehensive study published in the journal Pediatrics indicates that flu vaccines protect children well across Europe, with overall effectiveness remaining strong over two consecutive seasons. The data reveals that at least 65% of vaccinated children were protected in both the 2022–2023 and 2023–2024 periods, underscoring the consistent value of immunization in reducing the burden of respiratory infections in primary care settings.
While the general results are encouraging, the study highlights a persistent challenge: the H3N2 subtype. While vaccines showed high success rates against influenza B and H1N1, the H3N2 strain remains notably harder to stop, with effectiveness dropping as the virus evolves. This disparity underscores the ongoing battle between vaccine formulation and the rapid antigenic drift of certain influenza strains.
Tracking Effectiveness Across Viral Subtypes
The research utilized a test-negative case-control design across 10 study sites in nine countries within the European Union (EU) and European Economic Area (EEA). By analyzing children presenting with acute respiratory tract infections—characterized by cough, sore throat, or shortness of breath—researchers were able to compare the outcomes of vaccinated children against those who were not.
The results show a clear divide in how different strains respond to vaccination. In the 2022–2023 season, vaccine effectiveness (VE) against all influenza viruses was 68%. During this period, protection was highest against influenza B at 83%, followed by H1N1 at 57% and H3N2 at 54%.
The 2023–2024 season saw a shift in the dominant circulating strains. While overall effectiveness rose to 71%, the gap between subtypes widened. Protection against influenza B reached a high of 92% (though researchers note this specific figure should be interpreted cautiously as it was based on only three study sites), and H1N1 protection rose to 75%. Conversely, effectiveness against H3N2 declined to 40%.
| Virus Subtype | 2022–2023 VE | 2023–2024 VE |
|---|---|---|
| Influenza B | 83% | 92% |
| Influenza A (H1N1) | 57% | 75% |
| Influenza A (H3N2) | 54% | 40% |
| Overall Total | 68% | 71% |
Age-Based Variations and the H3N2 Challenge
As a physician and medical writer, I often emphasize that “one size does not fit all” in immunology. This study confirms that age plays a critical role in how the body responds to the flu shot. In the 2022–2023 season, children aged 0–8 years exhibited higher protection rates against H1N1 (70%) and influenza B (86%) compared to their older counterparts.
Interestingly, the older cohort (aged 9–17 years) showed stronger protection against the elusive H3N2 strain, with a VE of 63% during the first season. However, by the 2023–2024 season, protection against H3N2 remained modest across both age groups, suggesting that the virus’s ability to mutate—known as antigenic drift—often outpaces the annual updates to vaccine formulations.
The lower effectiveness against H3N2 is a known phenomenon in public health. This subtype is often associated with more severe seasons and is generally more prone to rapid evolution, making it a primary target for researchers seeking to improve the next generation of vaccines.
Closing the Evidence Gap in Primary Care
For years, there has been a scarcity of real-world data regarding how flu vaccines perform specifically within primary care pediatric practices across Europe. While the EU and EEA prioritize vaccination for high-risk children, the lack of comprehensive data across different age groups and vaccine types has made it difficult to refine immunization strategies.
This study helps fill that void by providing a granular appear at who is being protected and where the gaps remain. The researchers noted that the proportion of children in the vaccination target group among controls rose from 17% to 38% between the two seasons, indicating a shift in vaccination patterns and uptake.
Despite the success against H1N1 and B, the findings highlight an urgent need to increase overall vaccine uptake. By maximizing coverage, health systems can reduce the total volume of primary care visits and minimize the disruption to education caused by seasonal outbreaks.
What this means for parents and providers
The takeaway for families is that while no vaccine is 100% effective, the flu shot significantly reduces the likelihood of a child needing medical attention for influenza. The protection is particularly strong against the B and H1N1 strains, which are common causes of pediatric illness. Even when effectiveness is lower—as seen with H3N2—vaccination can still reduce the severity of the illness, potentially preventing more serious complications.
Medical providers are encouraged to continue monitoring age- and subtype-specific trends to guide timely vaccine updates and support the expansion of immunization strategies to cover both high-risk and healthy children.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Please consult a healthcare provider for personalized medical recommendations.
Public health officials and researchers will continue to track the evolution of the H3N2 strain and other subtypes to inform the composition of the next seasonal vaccine. Updated recommendations for the upcoming flu season are typically released by the World Health Organization (WHO) following their annual review of circulating strains.
We invite you to share your experiences with pediatric vaccination and join the conversation in the comments below.
